Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease

Click here to view online. Add this email to your safelist.

1 June 2020

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.